Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2006

Ikonisys Obtains Clearance for Prenatal Testing Application

  • Ikonisys’ fastFISH® auto-amniocyte application was cleared for marketing in the U.S. This product allows for the automated identification and enumeration of chromosomes 13, 18, 21, X, and Y in amniotic fluid cells via fluorescence in situ hybridization, or FISH.

    Numerical aberrations of these chromosomes are linked to birth defects, such as down syndrome. The fastFISH auto-amniocyte product is designed to run on the Ikoniscope® robotic digital microscopy platform.

    “We believe that physicians and consumers will appreciate fastFISH® auto-amniocyte’s rapid and reliable functionality,” says Petros Tsipouras, M.D., chairman and CEO.

    “Further, this application provides laboratories with an economical solution to the industry-wide shortage of trained technical personnel,” he adds.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »